Targeting Rare, Immunologic Disorders

James Mackay, president and CEO of Aristea Therapeutics, discusses the decision to spin out the company from AstraZeneca, its lead therapy in development for a rare immunologic disorder, and its collaboration and development deal with Arena Pharmaceuticals that gives its partner an option to acquire it outright.